Stock 6838 FORMOSA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Formosa Pharmaceuticals, Inc.

Equities

6838

TW0006838006

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-05-13 pm EDT 		5-day change 1st Jan Change
53.3 TWD 0.00% Intraday chart for Formosa Pharmaceuticals, Inc. +0.76% +6.71%
May. 09 Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery CI
Mar. 07 Formosa Pharmaceuticals, Inc. Announces FDA Approval for the NDA of A Global Innovative Hormone Nanosuspension Eye Drops CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals
AQ
Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
CI
Formosa Pharmaceuticals, Inc. Announces FDA Approval for the NDA of A Global Innovative Hormone Nanosuspension Eye Drops
CI
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
AQ
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
CI
US FDA approves Eyenovia's eye drug, Formosa Pharma says
RE
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery
CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Formosa Pharmaceuticals, Inc.(TPEX:6838) added to S&P Global BMI Index
CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery
CI
Grand Pharmaceutical Group's Eye Drops Show Safety in Phase 2, 3 Trials
MT
Formosa Pharmaceuticals, Inc. Announces Phase III Clinical Study of a Global Innovative Hormone Nanosuspension Eye Drops Successfully Reached Clinical Endpoint
CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Formosa Pharmaceuticals, Inc. Enter into A Collaboration Agreement with Eyenovia, Inc. for the Development of Novel Ophthalmic Therapeutics
CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery
CI
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6838 Stock
  4. News Formosa Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW